Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting · NCT04200443 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-05-01 | NCT04200443 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| City of Hope Medical Center | 347 |
| National Cancer Institute (NCI) | 3015 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Medical Center | Duarte | United States | 313 |
| Medical College of Wisconsin | Milwaukee | United States | 483 |
| Northwestern University | Chicago | United States | 727 |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City | United States | 197 |
| Washington University School of Medicine | St Louis | United States | 895 |